Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +3.23%49 ROC (Joel Greenblatt) % is 1.20% as of Dec. 2025, which is 100% below its 10-year median of 476.33. GuruFocus rates ASX:EZZ with a GF Score™ of 49/100 and a GF Value™ of A$1.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,322 Biotechnology companies, EZZ Life Science Holdings ranks better than 93.19% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. EZZ Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.20%.
The historical rank and industry rank for EZZ Life Science Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
ASX:EZZ'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 66.75 Med: 476.33 Max: 574.45
Current: 66.75
During the past 6 years, EZZ Life Science Holdings's highest ROC (Joel Greenblatt) % was 574.45%. The lowest was 66.75%. And the median was 476.33%.
ASX:EZZ's ROC (Joel Greenblatt) % is ranked better than 93.19% of 1322
companies
in the Biotechnology industry
Industry Median: -291.605
vs ASX:EZZ: 66.75
EZZ Life Science Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
EZZ Life Science Holdings (ASX:EZZ) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
EZZ Life Science Holdings ROC (Joel Greenblatt) % Related Terms
EZZ Life Science Holdings ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for EZZ Life Science Holdings's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings ROC (Joel Greenblatt) % Chart
ASX:EZZ vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's ROC (Joel Greenblatt) % falls into.
EZZ Life Science Holdings ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 1.20% mean?
EZZ Life Science Holdings (ASX:EZZ) has a ROC (Joel Greenblatt) % of 1.20% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on EZZ Life Science Holdings and its competitors. This is 100% below median its historical median of 476.33. Over the past decade, EZZ Life Science Holdings' ROC (Joel Greenblatt) % has ranged from 66.75 to 574.45. According to the industry distribution chart, EZZ Life Science Holdings ranks #90 out of 1322 companies in the Biotechnology industry, placing it in the top 6.8%.
Is EZZ Life Science Holdings' ROC (Joel Greenblatt) % too high?
EZZ Life Science Holdings' current ROC (Joel Greenblatt) % of 1.20% is 100% below median its 10-year median of 476.33. Over the past 10 years, this metric has ranged from a low of 66.75 to a high of 574.45. Based on the distribution chart, EZZ Life Science Holdings ranks #90 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #90 out of 1322 companies for ROC (Joel Greenblatt) %. This places EZZ Life Science Holdings in the top 7% of its industry — outperforming the majority of peers. Historically, EZZ Life Science Holdings' own ROC (Joel Greenblatt) % has ranged from 66.75 to 574.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on EZZ Life Science Holdings and its competitors. EZZ Life Science Holdings's current ROC (Joel Greenblatt) % is 1.20%, which is 100% below median its own 10-year median of 476.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is 1.20%, which is 100% below median its 10-year median of 476.33. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current ROC (Joel Greenblatt) % is 1.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
ROC (Joel Greenblatt) %: 1.20% (100% below median its 10-year median of 476.33)
GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
